Oxlumo Market Report 2026

Oxlumo Market Overview

• The Oxlumo market growth in the historic period has been driven by improved genetic screening for primary hyperoxaluria, limited historical treatment alternatives • Market expansion is supported by expansion of gene-silencing therapeutic pipelines, increasing investment in rare disease drug development • Growth Driver: Rising Focus On Personalized Medicine To Drive Growth In The Market • Market Trend: In Vivo Gene-Editing Therapies Drive Innovative Treatment Approaches • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Oxlumo Market?

Oxlumo (lumasiran) is a medication used to treat primary hyperoxaluria type 1, a rare genetic disorder that causes excessive oxalate production, leading to kidney damage. It works by inhibiting the enzyme HOGA1, which is involved in oxalate production. Oxlumo helps prevent kidney stones and kidney failure by reducing oxalate levels. It is administered as an injection under the skin (subcutaneous). The main types of clinical indications for oxlumo are primary hyperoxaluria type 1 (PH1), kidney stones, and end-stage renal disease (ESRD). Primary hyperoxaluria type 1 (PH1) is treated with Oxlumo (lumasiran), which reduces liver oxalate production to prevent kidney damage and failure. It is distributed by several distribution channels, such as retail pharmacies, and online pharmacies, and used by various end users, including pediatric, and adult.

What Is The Oxlumo Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of gene-silencing therapeutic pipelines, increasing investment in rare disease drug development, rising adoption of precision nephrology treatments, growing global access to genetic diagnostics, enhanced long-term disease management strategies. Major trends in the forecast period include increasing adoption of rna interference therapies, rising focus on genetic kidney disorders, expansion of precision medicine for rare diseases, growing use of subcutaneous targeted therapies, enhanced monitoring of metabolic disease progression.

What Are The Drivers Of The Oxlumo Market?

The increasing focus on personalized medicine is expected to boost the growth of the oxlumo market going forward. Personalized medicine refers to a medical approach that tailors treatment plans and therapies based on an individual’s genetic makeup, lifestyle, and environmental factors to achieve the most effective outcomes. The increasing focus on personalized medicine is attributed to advancements in genomics, allowing for more targeted and effective treatments based on individual genetics and lifestyle. Oxlumo (lumasiran) contributes to personalized medicine by targeting specific genetic mutations in individuals with primary hyperoxaluria type 1 (PH1), a rare genetic disorder, offering tailored treatment to reduce oxalate production and prevent kidney damage based on a patient's genetic profile. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based organization, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, an increase from six in 2022. Therefore, the increasing focus on personalized medicine is driving the growth of the oxlumo industry. The increasing prevalence of primary hyperoxaluria is expected to propel the growth of the oxlumo market going forward. Primary hyperoxaluria refers to a rare genetic disorder characterized by the overproduction of oxalate, which can lead to the formation of kidney stones, kidney damage, and other complications. The prevalence of primary hyperoxaluria is attributed to genetic mutations that impair the body's ability to metabolize oxalate, leading to its accumulation and potential kidney damage. Oxlumo assists in managing primary hyperoxaluria by inhibiting the enzyme alanine-glyoxylate aminotransferase (AGT), which lowers oxalate production and minimizes the risk of kidney damage. For instance, in October 2024, according to Kidney Care UK, a UK-based nonprofit organization, hyperoxaluria affects approximately 1 in 500,000 individuals in the UK. Type 1 is the most common form, accounting for 80% of cases, while Type 2 and Type 3 each represent around 10% of cases. Furthermore, in October 2023, according to the National Center for Biotechnology Information, a US-based national library of medicine, epidemiological data from Europe suggests that PH1 has an estimated prevalence of 1 to 3 cases per million. Therefore, the increasing prevalence of primary hyperoxaluria is driving the growth of the oxlumo industry.

Key Players In The Global Oxlumo Market

Major companies operating in the oxlumo market are Alnylam Pharmaceuticals Inc.

Global Oxlumo Market Trends and Insights

Major companies operating in the Oxlumo market are focusing on in vivo gene‑editing therapies, such as single‑dose CRISPR‑based treatments to inactivate the HAO1 gene, which encodes glycolate oxidase and thereby reduce oxalate production in the liver. In this context, an in vivo gene‑editing therapy means a treatment in which a gene editor (for example, a CRISPR/Cas nuclease) is delivered directly into a patient’s hepatocytes commonly via lipid nanoparticles (LNPs) to edit the target gene within the body, potentially achieving a durable or even one‑time cure. For instance, in August 2024, YolTech Therapeutics, a China‑based gene‑editing company, administered the first patient dose of YOLT‑203, its in vivo gene‑editing therapy for primary hyperoxaluria type 1 (PH1). YOLT‑203 is powered by YolTech’s proprietary YolCas12 editor, delivered via LNP‑mRNA, and is designed to target the HAO1 gene in hepatocytes. Key features of YOLT‑203 include its single‑dose, potentially curative design, the use of YolTech’s HEPDONE‑evolved Cas12 editor for high-efficiency, precision editing, and targeted delivery via lipid nanoparticle formulation, which enables liver-specific uptake.

What Defines the Oxlumo Market?

The oxlumo market consists of sales of oxlumo (lumasiran) injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Oxlumo Market Report 2026?

The oxlumo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the oxlumo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.